- Home
- / Novoheart
Novoheart
Revenue
$266 K
FY, 2019
Novoheart Summary
Company Summary
- Overview
- Novoheart is a biotechnology company that develops bioartificial human heart prototypes using a combination of stem cells and tissue engineering approaches. It engineers human heart constructs and further develops them into transplantable grafts for cell-based regenerative heart therapies.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2014
- HQ
- Vancouver, CA | view all locations
- Website
- https://www.novoheart.com/
- Cybersecurity rating
Table of Contents
Key People
Ronald Li, CEO & Scientific Co-Founder, Director
Katherine Ngan Ng Yu Ying, Director, Deputy Chair of the Board
Kevin Costa, CSO & Scientific Co-Founder
LocationsView all
5 locations detected
Vancouver, BC HQ
Canada
1430 W Pender St
Irvine, CA
United States
5171 California Ave #150
Vancouver, BC
Canada
2600-595 Burrard St
New Territories
Hong Kong
811, 15 Science Park W Ave, Science Park
Kowloon
Hong Kong
Millennium City Phase V, 418 Kwun Tong Rd, Kwun Tong
Novoheart Financials
Summary Financials
- Revenue (Q2, 2020)
- $C39.0K
- Gross profit (Q2, 2020)
- $C22.0K
- Net income (Q2, 2020)
- ($C1.9M)
- Cash (Q2, 2020)
- $C13.2M
- EBIT (Q2, 2020)
- ($C1.8M)